Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience

被引：10

作者：

Memoli, Mara ^{[1
,2
]}

Paviglianiti, Annalisa ^{[1
]}

Malard, Florent ^{[1
,3
,4
]}

Battipaglia, Giorgia ^{[1
,4
]}

Brissot, Eolia ^{[1
,3
,4
]}

Mediavilla, Clemence ^{[1
,4
]}

Bianchessi, Antonio ^{[1
,5
]}

Banet, Anne ^{[1
]}

Van de Wyngaert, Zoe ^{[1
]}

Ledraa, Tounes ^{[1
]}

Belhocine, Ramdane ^{[1
]}

Sestili, Simona ^{[1
]}

Lapusan, Simona ^{[1
]}

Hirsch, Pierre ^{[3
,4
,6
]}

Favale, Fabrizia ^{[3
,4
,6
]}

Boussaroque, Agathe ^{[3
,4
,6
]}

Bonnin, Agnes ^{[1
]}

Vekhoff, Anne ^{[1
]}

Legrand, Ollivier ^{[1
,3
,4
]}

Mohty, Mohamad ^{[1
,3
,4
]}

Dulery, Remy ^{[1
,3
,4
]}

机构：

[1] St Antoine Hosp, AP HP, Dept Hematol & Cellular Therapy, 184 Rue Faubourg St Antoine, F-75012 Paris, France

[2] Univ Naples Federico II, Hematol & Hematopoiet Stem Cell Transplant Ctr, Dept Med & Surg, Naples, Italy

[3] INSERM, UMRs 938, Paris, France

[4] Sorbonne Univ, Hop St Antoine, AP HP, Paris, France

[5] Univ Pavia, Dept Mol Med, Pavia, Italy

[6] Hop St Antoine, AP HP, Serv Hematol Biol, Paris, France

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 02期

关键词：

Thiotepa; busulfan; fludarabine; HSCT; TBF; myelofibrosis; STEM-CELL TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; LEUKEMIA WORKING PARTY; HAPLOIDENTICAL TRANSPLANTATION; EUROPEAN-SOCIETY; RISK-FACTORS; MARROW; SPLENECTOMY; RUXOLITINIB; MANAGEMENT;

D O I：

10.1080/10428194.2020.1827246

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10-42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23-65) at 3 years. The median follow-up period was 39 (range 14-60) months. Overall survival was 69% (95% CI, 50-83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.

引用

页码：419 / 427

页数：9

共 50 条

[41] Reduced Intensity Conditioning (Fludarabine and Busulfan) for Allogeneic Hematopoietic Cell Transplantation in Patients with Severe Aplastic Anemia
Chilkulwar, Abhishek
Sadashiv, Santhosh
Khan, Cyrus
Fazal, Salman
Mewawalla, Prerna
Kaminsky, Anna
Berteotti, Gina
Padhi, Parikshit
Lister, John
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S264 - S265
[42] Thiotepa-Busulfan-Fludarabine in Comparison to Busulfan-Cyclophosphamide As Myeloablative Conditioning Regimen Pre Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Saraceni, Francesco
Beohou, Eric
Labopin, Myriam
Arcese, William
Bonifazi, Francesca
Stepensky, Polina
Aljurf, Mahmoud
Bruno, Benedetto
Pioltelli, Pietro
Passweg, Jakob R.
Socie, Gerard
Santarone, Stella
Yakoub-Agha, Ibrahim
Savani, Bipin N.
Mohty, Mohamad
Nagler, Arnon
BLOOD, 2017, 130
[43] Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma
Kekre, Natasha
Marquez-Malaver, Francisco J.
Cabrero, Monica
Pinana, Jl
Esquirol, Albert
Soiffer, Robert J.
Caballero, Dolores
Terol, M. J.
Martino, Rodrigo
Antin, Joseph H.
Lopez-Corral, L.
Solano, Carlos
Armand, Philippe
Perez-Simon, Jose A.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) : 1808 - 1815
[44] Fludarabine and busulfan (FluBu regimen) as myeloablative conditioning regimen for allogeneic PBSCT in 71 leukaemic patients (a single centre study)
Iravani, M
Tavakoli, M
Shamshiri, AR
Evazi, MR
Mousavi, A
Bahar, B
Ghavamzadeh, A
BONE MARROW TRANSPLANTATION, 2005, 35 : S218 - S219
[45] Conditioning with fludarabine and targeted busulfan before transplantation of allogeneic hematopoietic stem cells.
Bornhaeuser, M
Storer, B
Slattery, JT
Appelbaum, FR
Deeg, HJ
Hansen, J
McDonald, G
Martin, PJ
Nichols, G
Radich, J
Woolfrey, A
Schleyer, E
Jenke, A
Thiede, C
Ehninger, G
Anasetti, C
BLOOD, 2002, 100 (11) : 213A - 213A
[46] Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
Fujimaki, K
Taguchi, J
Fujita, H
Hattori, M
Yamazaki, E
Takahashi, N
Fujisawa, S
Kanamori, H
Maruta, A
Ishigatsubo, Y
BONE MARROW TRANSPLANTATION, 2004, 33 (08) : 789 - 792
[47] CYCLOPHOSPHAMIDE FOLLOWED BY BUSULFAN CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - UMC LJUBLJANA, SLOVENIA SINGLE CENTER EXPERIENCE
Gredelj, Njetocka
Slajpah, Klara
Cemazar, Luka
Novak, Polona
Grzinic, Neda
Kraljic, Nika
Tomazin, Martina
Urdih, Tereza
Sever, Matjaz
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 273 - 273
[48] Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
K Fujimaki
J Taguchi
H Fujita
M Hattori
E Yamazaki
N Takahashi
S Fujisawa
H Kanamori
A Maruta
Y Ishigatsubo
Bone Marrow Transplantation, 2004, 33 : 789 - 792
[49] Impact of thiotepa-busulfan-fludarabine versus cyclophosphamide-based myeloablative conditioning regimen on outcomes after single unrelated cord blood transplantation for adults with haematological malignancies according to disease status
Bittencourt, H.
Ruggeri, A.
Sanz, G.
Nabhan, S.
Sanz, J.
Arcese, W.
Sirvent, A.
Ionescu, I.
Gluckman, E.
Rocha, V.
BONE MARROW TRANSPLANTATION, 2013, 48 : S61 - S61
[50] SINGLE CENTER EXPERIENCE OF THIOTEPA, TREOSULPHAN & FLUDARABINE BASED REGIMEN IN THALASSEMIA MAJOR
Choudhaty, D.
Katewa, S.
Khalya, G.
Anjan, M.
Setia, R.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S230 - S230

← 1 2 3 4 5 →